Clinical Trials Logo

Femoral Fracture clinical trials

View clinical trials related to Femoral Fracture.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06050668 Not yet recruiting - Muscle Atrophy Clinical Trials

Essential Amino Acid Supplementation for Femoral Fragility Fractures

Start date: February 2024
Phase: N/A
Study type: Interventional

This trial will evaluate the impact of 6 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

NCT ID: NCT05276674 Not yet recruiting - Femoral Fracture Clinical Trials

ZNN Bactiguard Retrograde Femoral Nails PMCF Study

Start date: August 2023
Phase:
Study type: Observational

Post-market clinical follow-up (PMCF) study to confirm the safety, performance, and clinical benefits of the intra-medullary retrograde femoral nail Zimmer Natural Nail (ZNN) Bactiguard (implants and instrumentation) when used for the temporary internal fixation and stabilization of femoral fractures.

NCT ID: NCT04918680 Not yet recruiting - Osteoarthritis, Hip Clinical Trials

Prospective Post-market Study Examining the Effectiveness of the EcoFit®

Start date: June 21, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and effectiveness of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery.

NCT ID: NCT01219712 Not yet recruiting - Clinical trials for Left Ventricular Dysfunction

Optimization Study of Cardiac Risk Patients With Hip Fracture

Start date: January 2011
Phase: N/A
Study type: Interventional

Elderly patients undergoing surgery for proximal hip fracture have a high risk of morbidity and mortality (M&M) postoperatively. Several studies including some from the investigators department have shown that there is a high risk of cardiovascular complications in this group of patients and 3-month mortality is 15-20%. One of the causes of this high M&M is the high incidence of cardiac failure associated with an increased NT-proBNP in this group of patients. The aim of the present study is to evaluate whether optimization of preoperative cardiac function can reduce cardiac M&M postoperatively. Following verbal consent, patients with an increased NT-proBNP would be randomized to goal-directed preoperative optimization or standard management according to current hospital routines. Following optimization, the patients would be transferred to the operating rooms and subsequent management including perioperative patient management would be left to the discretion of a specialist anesthesiologist who is directly involved in patient care. Postoperatively, Troponin T and NT-proBNP would be measured in all patients according to the study protocol. In addition, major adverse cardiac events would be documented and follow-up would be done by after 30 days and 3 months postoperatively.